ACE2-Fc Fusion Protein Against SARS-CoV-2
Author Information
Author(s): Bermúdez-Abreut Ernesto, Fundora-Barrios Talia, Hernández Fernández Diana Rosa, Noa Romero Enrique, Fraga-Quintero Anitza, Casadesús Pazos Ana V., Fernández-Marrero Briandy, Plasencia Iglesias Claudia A., Clavel Pérez Marilyn, Sosa Aguiar Katya, Sánchez-Ramírez Belinda, Hernández Tays
Primary Institution: Center of Molecular Immunology (CIM), Havana, Cuba
Hypothesis
Can an ACE2 silent Fc fusion protein effectively neutralize SARS-CoV-2 and its variants?
Conclusion
The ACE2-hFcLALA fusion protein shows potential as a therapeutic and preventive treatment against SARS-CoV-2 and its variants.
Supporting Evidence
- The ACE2-hFcLALA fusion protein effectively blocked the binding of SARS-CoV-2 to its receptor.
- It neutralized various SARS-CoV-2 variants in vitro.
- The fusion protein showed a higher efficacy against newer variants compared to the D614G strain.
Takeaway
Scientists created a special protein that can stop the COVID-19 virus from entering cells, which could help protect people from getting sick.
Methodology
The study involved creating an ACE2-hFcLALA fusion protein and testing its ability to block SARS-CoV-2 infection in cell cultures.
Limitations
The study primarily focused on in vitro results, which may not fully translate to in vivo effectiveness.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website